This Medudy course is a video tutorial for physicians on the topic “KEYNOTE-A18: Pembrolizumab Plus Radiochemotherapy for Locally Advanced Cervical Cancer.” The format used here is a “Journal Club Summary,” in which we summarize the latest and most clinically relevant studies for you.
Patients with locally advanced cervical cancer continue to face a significant risk of disease progression and death despite combined chemoradiotherapy, highlighting the need for more effective treatment approaches. The randomized, double-blind Phase 3 KEYNOTE-A18 trial is investigating whether adding the immune checkpoint inhibitor pembrolizumab to chemoradiotherapy followed by maintenance therapy improves progression-free survival and overall survival compared with chemoradiotherapy alone. This video provides context for the final analyses of the study presented at ASCO 2025.
Note: All “speakers” appearing in Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy team of doctors.
By the end of this course, you will know:
- the clinical background and relevance of the research question under investigation
- Study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
